Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced its second-quarter 2026 financial results, highlighting a significant reduction in operating expenses and a major regulatory milestone for its lead drug candidate. The company reported a 53% year-over-year decrease in operating expenses to $2.29 million, and a 47% reduction in general and administrative expenses to $1.76 million. These cost-cutting measures are part of a broader strategy to extend its cash runway and focus resources on key clinical development programs.
As of June 30, 2026, Quantum BioPharma held approximately $9.5 million in cash, cash equivalents, and digital assets, a substantial increase from $4.1 million at the end of 2025. Management stated that the current liquidity is sufficient to fund planned operations through at least October 2027, assuming the cash burn rate from the first half of 2026 remains consistent. This improved financial position provides the company with a stronger foundation to advance its pipeline.
Subsequent to the quarter-end, the U.S. Food and Drug Administration (FDA) approved Quantum’s Investigational New Drug (IND) application for Lucid-MS, a novel therapy for progressive multiple sclerosis (MS). The approval clears the way for a randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with progressive MS. Lucid-MS is a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical models, which is the underlying mechanism of MS. The progression to Phase 2 is a critical step in validating the drug’s efficacy in humans and brings hope to the MS community, which has limited treatment options for the progressive form of the disease.
According to the press release, Quantum BioPharma is dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly-owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS. The FDA’s approval of the IND application is a testament to the promising preclinical data and the company’s commitment to advancing this potential therapy.
The company also retains an ownership stake in Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), which markets the OTC version of its alcohol misuse product, UNBUZZD. Quantum owns approximately 19.84% of Unbuzzd as of March 31, 2026, and is entitled to royalty payments of 7% on sales of the product until payments total $250 million, after which the royalty drops to 3% in perpetuity. This arrangement provides an additional potential revenue stream for Quantum as Unbuzzd grows its market presence.
“We are pleased with the progress we have made in reducing costs while advancing our lead asset,” said a company spokesperson. “The FDA’s approval of our IND application for Lucid-MS is a major milestone, and we are eager to initiate the Phase 2 trial. With a strengthened balance sheet, we are well-positioned to execute on our clinical development plans.”
For more information on Quantum BioPharma and its recent developments, visit the company’s newsroom at https://nnw.fm/QNTM.
